 |
市场调查报告书
商品编码
1672653
冷冻干燥药物市场：依药物类别、适应症、包装类型、通路和地区划分Lyophilized Drugs Market, By Drug Class, By Indication, By Packaging Type, By Distribution Channel, By Geography |
||||||
价格
简介目录
2025 年全球冻干药品市场规模预计为 3,710.9 亿美元，预计到 2032 年将达到 6,831.8 亿美元，2025 年至 2032 年的复合年增长率为 9.1%。
| 报告范围 | 报告详细信息 | ||
|---|---|---|---|
| 基准年 | 2024 | 2025 年市场规模 | 3710.90亿美元 |
| 效能资料 | 从 2020 年到 2024 年 | 预测期 | 2025 至 2032 年 |
| 预测期：2025-2032年复合年增长率： | 9.10% | 2032 年价值预测 | 6831.8亿美元 |
数字。 2025 年冻干药物市场占有率（按地区划分）
全球冷冻干燥药物市场的成长得益于冷冻干燥药物的各种优势，例如提高稳定性、易于管理和降低运输成本。冷冻干燥有助于去除製剂中的水分，防止微生物生长，从而延长药品的保质期。无需冷藏即可储存和运输药品。由于慢性病的增加和製药公司对新型药物输送解决方案的研发投入增加，预计预测期内对冷冻干燥药物的需求将大幅增加。
市场动态：
全球冻干药物市场的发展受到老年人口不断增长、慢性病患病率上升以及冻干药物保质期更长、微生物污染风险更低等优势的推动。然而，预计冷冻干燥设备和程序的高成本将抑制市场的成长。另一方面，由于医疗基础设施的改善和医疗支出的增加，亚太和拉丁美洲的新兴市场预计将为市场参与者提供丰厚的机会。此外，对新型、更高效的冷冻干燥技术的持续研究和开发将在预测期内进一步为全球市场的扩张创造机会。
本研究的主要特点
- 本报告对全球冻干药物市场进行了详细分析，并提供了预测期（2025-2032）的市场规模（十亿美元）和年复合成长率（CAGR%），假设 2024 年为基准年。
- 它还强调了各个领域的潜在商机并解释了该市场的有吸引力的投资提案矩阵。
- 它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
- 全球冷冻干燥药物市场的主要企业是根据公司亮点、产品系列、关键亮点、财务绩效和策略等参数进行的分析。
- 本报告的见解将使负责人和企业经营团队能够就未来产品发布、高端市场策略、市场扩张和行销策略做出明智的决策。
- 全球冻干药物市场报告针对该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
- 相关人员可以透过用于分析全球冻干药物市场的各种策略矩阵来促进决策。
目录
第一章 调查目的与前提条件
- 研究目标
- 先决条件
- 简称
第二章 市场展望
- 报告描述
- 市场定义和范围
- 执行摘要
- Coherent Opportunity Map（COM）
第三章市场动态、法规与趋势分析
- 市场动态
- 驱动程式
- 限制因素
- 机会
- 影响分析
- 市场趋势
- 主要进展
- 监管情景
- 收购和合作场景
- 资金筹措和投资
- PEST分析
- 波特的分析
4. 全球冷冻干燥药物市场-冠状病毒（COVID-19）大流行的影响
- 整体影响
- 政府倡议
- COVID-19 市场影响
5. 2020 年至 2032 年全球冷冻干燥药物市场（依药品类别划分）（十亿美元）
- 抗感染
- 抗癌药物
- 利尿剂
- 质子帮浦抑制剂
- 麻醉剂
- 抗凝血剂
- NSAID
- 其他的
6. 2020-2032 年全球冷冻干燥药物市场（按包装类型划分）（十亿美元）
- 管瓶
- 注射
- 墨水匣
7. 2020-2032 年全球冻干药物市场按分销管道划分（十亿美元）
- 医院药房
- 零售药局
- 网路药局
8. 2020 年至 2032 年全球冷冻干燥药物市场（依适应症划分）（十亿美元）
- 肿瘤学
- 感染疾病
- 自体免疫疾病
- 消化系统疾病
- 皮肤病
- 呼吸系统疾病
- 眼科疾病
- 荷尔蒙失调
- 其他的
9. 2020 年至 2032 年全球冷冻干燥药物市场（按地区划分）（十亿美元）
- 北美洲
- 拉丁美洲
- 欧洲
- 亚太地区
- 波湾合作理事会
- 以色列
- 其他中东地区
- 非洲
- 北非
- 中部非洲
- 南非
第十章 竞争格局
- 公司简介
- Pfizer Inc.
- Novartis AG
- Roche Holding AG
- Johnson &Johnson
- Sanofi SA
- Amgen Inc.
- AbbVie Inc.
- Merck &Co., Inc.
- Eli Lilly and Company
- AstraZeneca PLC
- Bristol Myers Squibb Company
- GlaxoSmithKline plc
- Gilead Sciences, Inc.
- Biogen Inc.
- Teva Pharmaceutical Industries Ltd.
- Mylan NV
- Celgene Corporation
- Novo Nordisk A/S
- Vertex Pharmaceuticals Incorporated
- Takeda Pharmaceutical Company Limited
第 11 章 分析师建议
- 命运之轮
- 分析师观点
- 一致的机会图
第 12 章参考文献与调查方法
- 参考
- 调查方法
简介目录
Product Code: CMI2930
Global Lyophilized Drugs Market is estimated to be valued at USD 371.09 Bn in 2025 and is expected to reach USD 683.18 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.1% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 371.09 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 9.10% | 2032 Value Projection: | USD 683.18 Bn |
Figure. Lyophilized Drugs Market Share (%), By Region 2025
The global lyophilized drugs market growth is driven by various advantages associated with lyophilization of drugs such as improved stability, ease of administration, and reduced transportation costs. Lyophilization or freeze-drying helps extend the shelf life of drugs by removing water from the formulations, thereby preventing the growth of microorganisms. It also enables storage and transportation of drugs without refrigeration. With the growing prevalence of chronic diseases and increasing R&D investments of pharmaceutical companies in novel drug delivery solutions, the demand for lyophilized drugs is expected to rise substantially during the forecast period.
Market Dynamics:
The global lyophilized drugs market is driven by the growing geriatric population, rising incidence of chronic diseases, and advantages of lyophilized drugs such as longer shelf life and lower risk of microbial contamination. However, high costs associated with lyophilization equipment and procedures are expected to restrain the market growth. On the other hand, emerging markets of Asia Pacific and Latin America are likely to offer lucrative opportunities for market players owing to improving healthcare infrastructure and increasing healthcare spending in these regions. Additionally, ongoing research for development of novel and more efficient lyophilization technologies will further create opportunities for the expansion of the global market during the forecast period.
Key Features of the Study:
- This report provides in-depth analysis of the global lyophilized drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global lyophilized drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer Inc., Baxter International Inc., Jadavpur University, Merck & Co., Inc., and GlaxoSmithKline plc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global lyophilized drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lyophilized drugs market
Detailed Segmentation-
- By Drug Class
- Anti-infective
- Antineoplastic
- Diuretics
- Proton Pump Inhibitor
- Anesthetic
- Anticoagulant
- NSAID's
- Others
- By Indication
- Oncology
- Infectious Disease
- Autoimmune Disease
- Gastrointestinal Disease
- Dermatological Disorders
- Respiratory Diseases
- Ophthalmic Diseases
- Hormonal Disorders
- Others
- By Packaging Type
- Vial
- Injection
- Cartridge
- By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Pfizer Inc.
- Novartis AG
- Roche Holding AG
- Johnson & Johnson
- Sanofi S.A.
- Amgen Inc.
- AbbVie Inc.
- Merck & Co., Inc.
- Eli Lilly and Company
- AstraZeneca PLC
- Bristol Myers Squibb Company
- GlaxoSmithKline plc
- Gilead Sciences, Inc.
- Biogen Inc.
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Celgene Corporation
- Novo Nordisk A/S
- Vertex Pharmaceuticals Incorporated
- Takeda Pharmaceutical Company Limited
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Indication
- Market Snapshot, By Packaging Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Acquisitions and Partnerships Scenario
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. Global Lyophilized Drugs Market - Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the Market
5. Global Lyophilized Drugs Market, By Drug Class, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Anti-infective
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Antineoplastic
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Diuretics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Proton Pump Inhibitor
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Anesthetic
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Anticoagulant
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- NSAID's
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Lyophilized Drugs Market, By Packaging Type, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Vial
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Injection
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Cartridge
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Lyophilized Drugs Market, By Distribution Channel , 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Lyophilized Drugs Market, By Indication, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oncology
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Infectious Disease
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Autoimmune Disease
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Gastrointestinal Disease
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Dermatological Disorders
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Respiratory Diseases
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ophthalmic Diseases
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hormonal Disorders
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Lyophilized Drugs Market, By Region, 2020 - 2032, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021-2032
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel2019 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Company Profiles
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Roche Holding AG
- Johnson & Johnson
- Sanofi S.A.
- Amgen Inc.
- AbbVie Inc.
- Merck & Co., Inc.
- Eli Lilly and Company
- AstraZeneca PLC
- Bristol Myers Squibb Company
- GlaxoSmithKline plc
- Gilead Sciences, Inc.
- Biogen Inc.
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Celgene Corporation
- Novo Nordisk A/S
- Vertex Pharmaceuticals Incorporated
- Takeda Pharmaceutical Company Limited
- Pfizer Inc.
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About Us and Sales Contact
